Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Heba Yassin et al.|Blood Neoplasia|2024Cited by 36
RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencingMuxin Gu, George S. Vassiliou, Maximilian Zwiebel et al.|Haematologica|2019Cited by 24
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapyJad Othman, Richard Dillon, Angela Hwang et al.|Blood Advances|2024Cited by 10
The Role of EZH2 in the Induction and Maintenance of Acute Myeloid LeukaemiaFaisal Basheer|Apollo (University of Cambridge)|2018Cited by 0